Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data on breast cancer detailed by researchers at University of Pennsylvania, Medical Department
May 1st, 2008
According to a study from the United States, "Prolactin receptors (PRLr) expressed in a majority of breast cancer are activated by prolactin and growth hormone. The PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser(349), which, when phosphorylated, recruits the beta Trcp E3 ubiquitin ligase and facilitates PRLr degradation." "Here, we show that constitutive oncogenic signaling downstream of ErbB2 and Ras stabilizes PRLr via inhibitory phosphorylation of glycogen synthase kinase-3 beta (GSK3 beta) on Ser(9). Importantly, inactivation of GSK beta correlates with elevated levels of PRLr protein in clinical human breast...
Source: Women's Health Weekly (2008-05-01)
|
